Study of infections caused by drug-resistant bacteria
Part of Infections clinical trials.
This study looks at patients who have severe infections caused by carbapenem-resistant Enterobacterales (CRE), which are bacteria that are hard to treat because they resist many antibiotics. It will examine the germs and how patients respond to newer antibiotics that are specifically used for these tough infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have an infection caused by carbapenem-resistant Enterobacterales (CRE).
- The infection must be in one of these areas: lungs (pneumonia), urine (urinary tract infection), abdomen (intra-abdominal infection), spine (spondylodiscitis), or blood (bloodstream infection).
- You must have received at least one dose of one of these antibiotics: ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol.
- You must agree to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called colistimethate sodium for people in the hospital with a serious infection (pneumonia or bloodstream infection) caused by a resistant bacteria called CRE. The goal is to see if this antibiotic can effectively treat the infection.
This study looks at bacteria that are resistant to strong antibiotics called carbapenems. It does not require participants, as it examines bacteria samples already collected.
This study looks at factors that make some hospitalized children in the pediatric intensive care unit (PICU) develop or carry germs called carbapenem-resistant Enterobacteriaceae. It aims to understand who is at higher risk and why, which may help prevent infections in the future.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
This trial tests whether giving healthy bacteria through capsules (a fecal transplant) can help get rid of CRE, a type of bacteria that is hard to treat because it resists many antibiotics. If successful, this could reduce the risk of serious infections.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
Hear when a new Carbapenem-Resistant Enterobacteriaceae Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.